FY2024 EPS Estimates for Prothena Raised by Zacks Research

Prothena Co. plc (NASDAQ:PRTA) – Investment analysts at Zacks Research raised their FY2024 earnings per share estimates for shares of Prothena in a research note issued on Tuesday, December 3rd. Zacks Research analyst E. Bagri now anticipates that the biotechnology company will post earnings of ($2.36) per share for the year, up from their prior estimate of ($2.47). The consensus estimate for Prothena’s current full-year earnings is ($2.25) per share. Zacks Research also issued estimates for Prothena’s Q1 2025 earnings at ($1.33) EPS, Q2 2025 earnings at ($1.38) EPS, Q3 2025 earnings at ($1.33) EPS, Q4 2025 earnings at $0.78 EPS, FY2025 earnings at ($3.25) EPS, Q1 2026 earnings at ($1.42) EPS, Q2 2026 earnings at ($1.14) EPS, Q3 2026 earnings at ($0.20) EPS and FY2026 earnings at ($3.11) EPS.

Prothena (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.18) by $0.08. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The company had revenue of $0.97 million during the quarter, compared to the consensus estimate of $1.22 million. During the same period in the previous year, the firm earned $0.38 earnings per share. Prothena’s revenue for the quarter was down 98.9% on a year-over-year basis.

Other analysts have also issued research reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Prothena in a research note on Monday, September 30th. Bank of America dropped their price target on shares of Prothena from $33.00 to $31.00 and set a “neutral” rating on the stock in a research note on Tuesday, October 1st. Royal Bank of Canada decreased their price objective on shares of Prothena from $28.00 to $24.00 and set a “sector perform” rating for the company in a research report on Friday, August 9th. StockNews.com downgraded Prothena from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. Finally, Oppenheimer reduced their price target on Prothena from $66.00 to $62.00 and set an “outperform” rating for the company in a report on Wednesday, August 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Prothena has an average rating of “Moderate Buy” and an average target price of $61.86.

Prothena Trading Down 4.1 %

Shares of Prothena stock opened at $13.93 on Friday. The company has a fifty day moving average price of $16.37 and a 200 day moving average price of $19.62. The stock has a market cap of $749.57 million, a price-to-earnings ratio of -5.62 and a beta of 0.09. Prothena has a twelve month low of $13.22 and a twelve month high of $41.54.

Institutional Trading of Prothena

Institutional investors and hedge funds have recently modified their holdings of the business. Signaturefd LLC grew its position in shares of Prothena by 182.1% during the 2nd quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 863 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Prothena by 13.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company’s stock valued at $211,000 after acquiring an additional 1,186 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Prothena by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company’s stock worth $173,000 after purchasing an additional 4,026 shares during the period. Intech Investment Management LLC bought a new position in Prothena during the 3rd quarter worth $210,000. Finally, XTX Topco Ltd bought a new position in Prothena during the 3rd quarter worth $260,000. 97.08% of the stock is owned by institutional investors and hedge funds.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.